Whole-Brain Atrophy Rate in Idiopathic Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy
In multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), the absence of surrogate endpoints makes clinical trials long and expensive. We aim to determine annualized whole-brain atrophy rates (a-WBAR) in idiopathic Parkinson’s disease (IPD), MSA, and PSP. Ten healthy controls, 20 IP...
Saved in:
| Main Authors: | C. Guevara, K. Bulatova, G. J. Barker, G. Gonzalez, N. Crossley, M. J. Kempton |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2016/9631041 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Cognitive Profile and Executive Function of Progressive Supranuclear Palsy and Multiple System Atrophy Patients
by: Divya Goel, et al.
Published: (2019-04-01) -
Sensitivity and Specificity of the ECAS in Parkinson’s Disease and Progressive Supranuclear Palsy
by: Jennifer A. Foley, et al.
Published: (2018-01-01) -
Zolpidem in Progressive Supranuclear Palsy
by: Sandip K. Dash
Published: (2013-01-01) -
Validation of the Parkinson’s Disease Caregiver Burden Questionnaire in Progressive Supranuclear Palsy
by: Martin Klietz, et al.
Published: (2021-01-01) -
Comparative study of nonmotor symptoms in progressive supranuclear palsy and Parkinson’s disease
by: Ying Chen, et al.
Published: (2025-05-01)